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Simple Summary: Despite advancements in surgical oncology and chemoradiation therapies, pancre-
atic cancer still has one of the lowest 5-year survival rates in the United States. The silent progression
of this disease often leads to it being identified after it has already reached an advanced and often
unresectable stage. The field of interventional oncology has yielded ablation strategies with the
potential to downstage and increase survival rates in patients suffering from locally advanced pan-
creatic cancer. This review examines the treatment strategies for locally advanced pancreatic cancer,
discussing current results and future directions.
Abstract: The insidious onset and aggressive nature of pancreatic cancer contributes to the poor
treatment response and high mortality of this devastating disease. While surgery, chemotherapy
and radiation have contributed to improvements in overall survival, roughly 90% of those afflicted
by this disease will die within 5 years of diagnosis. The developed ablative locoregional treatment
modalities have demonstrated promise in terms of overall survival and quality of life. In this review,
we discuss some of the recent studies demonstrating the safety and efficacy of ablative treatments in
patients with locally advanced pancreatic cancer.
Keywords: pancreatic cancer; interventional; oncology; ablation; IRE; microwave; cryoablation
1. Introduction
Pancreatic cancer is the fourth leading cause of cancer-related death in the United
States, with a 5-year survival of approximately 9% [1]. Risk factors include smoking, obesity,
and type 2 diabetes. Approximately 80–85% of the patients present with unresectable or
metastatic disease. The American Cancer Society estimated that, in 2020, there will be
57,600 people diagnosed with pancreatic cancer and 47,050 related deaths. The high
mortality of pancreatic cancer is primarily due to the insidious progression of this disease,
resulting in a delayed diagnosis and often advanced disease at presentation. At the time
of diagnosis, around 35% of patients have locally advanced disease (Stage III) and 50% of
patients have metastatic disease (Stage IV). Furthermore, the aggressive tumor biology of
pancreatic cancer contributes to early recurrence and metastasis in addition to resistance
to chemotherapy and radiotherapy [2,3]. This review article is an overview of the current
treatment options available in the management of pancreatic cancer, with a special focus
on percutaneous ablation using irreversible electroporation and future directions.
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2. Treatment Options for Locally Advanced Pancreatic Cancer
2.1. Surgery
Less than 20% of patients with pancreatic cancer are resectable at diagnosis. The most
common surgery is the Whipple operation, where the pancreatic head, duodenum, gall-
bladder, and the antrum of the stomach are removed, with drainage of the distal pancreatic
duct and biliary system accomplished through anastomosis to the jejunum. The overall
mortality rate from a Whipple procedure is approximately 4–5%, with morbidity rates
around 30–50% [4–6]. The most common postoperative complications include delayed
gastric emptying occurring in 11–29% of patients, postoperative pancreatic fistula in 2–20%,
postoperative abscess formation in 9–13%, bile leak in 2–8%, and post-pancreatectomy hem-
orrhage in 1–8% [4,7,8]. Variations include the pylorus sparing pancreaticoduodenectomy
(PPPD) procedure, which is modified with the goal of improving nutritional deficiencies
encountered in patients post-antrectomy [9]. A distal pancreatectomy is utilized in patients
with tumors involving the body and the tail. A total pancreatectomy, which is a combina-
tion of both, is reserved for large tumors and has the highest associated mortality [9].
Surgical resection imparts improved survival to 23 months when a tumor-free margin
of 1 mm (R0 resection) can be achieved. Survival is increased to 35 months when a greater
than 1 mm tumor-free margin (R0 wide) can be achieved. The survival advantage of the
resection is mostly lost when the tumor is detected within 1 mm of the resection margin.
Of the approximately 15% of patients who undergo surgical resection, 5-year survival
is 12% to 18% [1,2]. Patients undergoing curative resection for pancreatic cancer mostly
develop recurrent tumor disease, with 69–75% of patients relapsing within 2 years and
80–90% relapsing within 5 years. The role of adjuvant and neoadjuvant treatments to
improve surgical outcomes have been studied. The PRODIGE-24 ACCORD trial com-
pared 6 months of adjuvant chemotherapy with modified FOLFIRINOX (FOLinic acid,
Fluorouracil, IRINotecan and OXaliplatin) to gemcitabine monotherapy. The combination
therapy group had increased disease-free survival of 21.6 months vs. 12.8 months and
improved median overall survival of 54.4 months vs. 35 months [10].
The advantages of chemotherapy in the neoadjuvant setting include patient selection
(those who progress with neoadjuvant therapy can avoid surgery), testing of chemosensi-
tivity, higher rate of completion of systemic therapy, tumor control, and downstaging to
R0 resection. The disadvantage is the toxicity of neoadjuvant treatment, which can limit
the possibility of surgical resection. In the neoadjuvant setting, a meta-analysis by Petrelli
et al. on FOLFIRINOX-based neoadjuvant therapy concluded that it resulted in a 39.4% R0
resection rate [11].
2.2. Chemotherapy
In patients with a good performance status, the standard of care for LAPC is the
FOLFIRINOX or dose-attenuated modified FOLFIRINOX regimen [2,3,12]. A meta-analysis
conducted by Suker et al. demonstrated that treatment-naïve patients with unresectable
LAPC had a median overall survival (OS) of 24.2 months (95% CI, 21.7–26.8) and progression-
free survival (PFS) of 15.0 months (95% CI, 13.8–16.2) when treated with FOLFIRINOX [3].
In this study, successful resection was possible following chemotherapy in approximately
25% of patients [3]. However, in the same meta-analysis, when comparing studies that
evaluated adverse events, treatment with FOLFIRINOX resulted in a grade 3 or 4 adverse
event rate of 60.4 events per 100 patients. For patients that cannot tolerate FOLFIRINOX
treatment, second-line treatment options include combination therapy with gemcitabine
and nab-paclitaxel. In those with a poor performance status, gemcitabine alone is the
preferred chemotherapy [2,13]. While these chemotherapeutics confer a small increase in
survival, the prognosis is still very poor in patients with unresectable LAPC.
2.3. Radiotherapy
The role of radiotherapy in LAPC has been controversial, with previous studies
demonstrating equivalent or inferior results when used in conjunction with chemotherapy.
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In the FFCD/SFRO study, the authors investigated the use of adjuvant radiotherapy in
LAPC by comparing chemoradiotherapy to chemotherapy alone in a randomized phase
III clinical trial. Specifically, this study compared intensive induction chemoradiotherapy
(60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine
to gemcitabine alone. Chemoradiotherapy was found to be more toxic and less effective
than chemotherapy alone, with a median OS of 8.6 versus 13 months (p = 0.03), and toxicity
(grades 3 and 4) of 36% versus 22% during the induction phase and 32% versus 18% during
maintenance [14]. Another trial that compared chemoradiotherapy with chemotherapy
was the LAP07 study. This was a two-stage randomization trial. In the first stage, patients
were randomized to receive gemcitabine alone (n = 223) or gemcitabine with erlotinib
(n = 219) for four months. Patients with progression-free disease were further randomized
to receive two more months of the same chemotherapy (n = 136) or chemoradiotherapy
(54 Gy plus capecitabine) (n = 133). No significant difference in the median OS was noted
between chemotherapy (16.5 months) and chemoradiotherapy (15.2 months) (hazard ratio
(HR), 1.03; 95% CI, 0.79–1.34; p = 0.83) [15]. Altogether, the FFCD/SFRO and LAP07 studies
demonstrated that adjuvant radiotherapy has limited utility and possibly results in poorer
outcomes in LAPC patients.
Advances in radiation include SBRT and MgRT. SBRT is delivered within five fractions
and delivers a high dose to the tumor, with a steep falloff to much lower doses within a
few millimeters outside of the tumor. The most recent publication on ablative radiation
therapy and survival in inoperable pancreatic cancer patients and the role of SBRT included
119 consecutive patients treated with A-RT [16]. All patients with localized, unresectable, or
medically inoperable pancreatic cancer with tumors of any size and less than 5 cm luminal
abutment with the primary tumor were eligible. Ablative RT (98 Gy biologically effective
dose) was delivered using standard equipment. Median OS from diagnosis and A-RT was
26.8 and 18.4 months, respectively. The study concluded that patients with inoperable
LAPC treated with A-RT following multiagent induction therapy were associated with
durable locoregional tumor control and favorable survival.
Magnetic resonance-guided radiation therapy (MRgRT) technology makes it possible
to have continuous imaging of the tumor and nearby organs and automatically turns the
beam on and off based on tumor positioning throughout respiration. MRgRT can safely
deliver the ablative dose, which is at least twice as high as conventional SBRT. A recently
published retrospective multicenter analysis using MRgRT showed that ablative doses of
around the equivalent of 100 Gy using standard fraction sizes result in improved local
control and OS when compared with the use of conventional lower doses [17].
2.4. Ablation
Despite advances in surgical techniques, chemotherapy, and radiation therapy, the
incidence and mortality rate for pancreatic cancer have remained parallel to each other.
This lack of substantial improvement points to aggressive cancer biology. The tumor
microenvironment, particularly the interaction of the stromal elements with the cancer
cells, has been postulated to confer resistance to treatment, early recurrence, and metasta-
sis [18,19]. As a corollary to application in other solid organ tumors and to circumvent the
resistance-conferring property of the tumor stroma, direct tumor treatment using ablative
modalities has been attempted. Various ablative modalities (Table 1) used for pancreatic
cancer include radiofrequency ablation, microwave ablation, cryoablation, high-intensity
focused ultrasound, photodynamic therapy, and irreversible electroporation [20,21].
2.4.1. Radiofrequency Ablation
Radiofrequency ablation (RFA) is a thermal ablative modality in which the application
of alternative current in the radiofrequency range causes ionic agitation in the tumor,
leading to frictional heat generation. Sufficient heat generation leads to tumor death by
coagulative necrosis. RFA is one of the oldest ablative technologies and has the advantages
of widespread availability and low cost. While there is extensive literature on the role of
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RFA in the treatment of primary and metastatic disease to the liver, the data on the use of
RFA in primary pancreatic cancer are limited. Earlier studies with RFA were associated
with high morbidity and mortality. Subsequent refinement in technique allowed further
experience with RFA [20]. Ruarus et al. published a detailed review of ablative therapies in
LAPC [21]. This review reported on six studies—each with more than ten patients—four of
which were prospective and two that were retrospective. All six studies emanated from the
same institution, with a percutaneous approach used only in one study. In the remaining
five studies, ablation was performed during laparotomy with a likely overlapping patient
population. Overall survival was reported in four of these studies, with a range of 19.0
to 25.6 months. Morbidity and 30-day mortality were in the range of 0–28% and 0–3%,
respectively. Serious adverse events included pancreatic fistula, acute pancreatitis, portal
vein thrombosis, duodenal injury, biliary injury, gastric ulcer or fistula, hemoperitoneum,
and liver failure. Causes of mortality were hepatic failure, sepsis following a duodenal
perforation, severe acute pancreatitis, and duodenal hemorrhage. These studies, albeit
limited, suggest that RFA is an option for treating unresectable LAPC.
Table 1. Comparison of ablative modalities in pancreatic cancer.
Procedure Mechanism of Action Advantages Limitations
Radiofrequency ablation (RFA)
Utilizes alternating electrical
current to create a thermal
ablation zone in the tissue.
Inexpensive compared to other
ablation modalities.
Widespread availability.








Creates a zone of ablation by
generating frictional heat through
agitation of water molecules.
Relatively larger ablation zones
and faster ablation times
compared to RFA. Does not
require grounding pads.
Possible adverse events include
mild pancreatitis, asymptomatic
hyperamylasemia, pancreatic
ascites, and minor bleeding.
Cryoablation
Utilizes changes in argon gas
pressure to generate freeze–thaw
cycles (i.e., the Joule–Thomson
effect) in the tissue. The probe tip
can reach temperatures as low as
−185 ◦C, inducing cell death in
the surrounding tissue.
Good visualization of ice ball, and
less postoperative pain and
damage to nearby critical




or bile leak, gastrointestinal
bleeding or obstruction, delayed
gastric emptying, infection, or
intra-abdominal bleeding.
Irreversible electroporation (IRE)
Nonthermal process uses DC
surrent to create permanent pores
in cell membrane, increasing the
permeability and inducing
cell death.
Nonthermal and is not limited by
the heat-sink effect like the
thermal ablation modalities.
Preferred method when working
near vascular and other
critical structures.
Risk for generating cardiac
arrhythmias. Need for general
anesthesia with cardiac monitoring
and muscle relaxation. Probe
placement has to be parallel.
2.4.2. Microwave Ablation
Microwave ablation (MWA) uses alternating electromagnetic pulses in the microwave
range, causing dielectric heating of the water molecules. As in RFA, coagulative necrosis
is the mechanism of tumor destruction. Compared to RFA, microwave ablation offers
advantages of active heating, larger ablations in shorter time, and does not require the
placement of a grounding pad. Limited data are available on the application of MWA in
pancreatic cancer. Lygidakis et al. published a retrospective study of 15 patients undergoing
MWA during laparotomy. They reported partial necrosis in all patients, with no major
morbidity or mortality. Minor complications were reported in 6/15 patients and included
mild pancreatitis, asymptomatic hyperamylasemia, pancreatic ascites, and minor bleeding.
Survival data were not reported [22]. In another retrospective study of ten patients (five
percutaneous, five laparotomy), Carrafiello et al. reported 100% efficacy, with 9-month
and 1-year local tumor progression rates of 37.5% (3/8) and 62.5% (5/8), respectively. In
this study, they had two patients with minor complications and two major adverse events
(pancreatitis and pseudoaneurysm of the gastroduodenal artery) [23].
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Although a direct comparison of RFA and MWA has not yet been performed, results
of single-arm retrospective studies hint towards more favorable outcomes with MWA in
terms of safety and feasibility. One such study by Vogl et al. conducted retrospective
reviews of computed tomography (CT)-guided percutaneous MWA using a 2.45 GHz
device in 20 patients, and 22 tumors/sessions were published [24]. Seventeen tumors
were in the pancreatic head and five in the pancreatic tail, with a mean tumor diameter
of 30 ± 6 mm. In this study, there was a technical success rate of 100% with no major
adverse events, with only two patients reporting severe local pain post-ablation. At a short
3-month imaging follow-up, progression was seen in only 1 out of 10 tumors with available
follow-up imaging. While survival data are not currently available to evaluate the efficacy
of MWA, this study suggests that MWA is a safer option for locoregional therapy of LAPC.
2.4.3. Cryoablation
In cryoablation, argon gas is passed through a needle core utilizing the Joule–Thomson
effect; rapid freeze and thaw cycles lead to cellular destruction mediated by cell membrane
disruption, vascular damage, and ischemia [21]. Cryoablation offers the advantage of
multiprobe placement, visualization of the ice-ball or ablation zone, and being MRI com-
patible. In LAPC, outcomes of cryoablation plus bypass surgery were compared with those
of bypass surgery alone in two separate studies [25,26]. Despite tumor shrinkage in the
cryoablation plus bypass surgery group, OS was not statistically different (350 days versus
257 days, p = 0.124: 5 months versus 4 months, p > 0.05). Patients receiving cryoablation
experienced higher incidence of post-operative delayed gastric emptying. Postoperative
complications included pancreatic or bile leak, gastrointestinal bleeding or obstruction,
delayed gastric emptying, infection, or intra-abdominal bleeding [25,26].
The utility of cryoablation for treating pancreatic cancer via the percutaneous approach
has been assessed by Niu et al. in a retrospective review of 32 patients undergoing
49 ablations [27]. Tumor size ranged from 2 to 11 cm, with a mean of 5.2 cm ± 8 cm.
Disease stage distribution included stage II (n = 3), stage III (n = 11), and stage IV (n = 18),
with no patient deaths or major complications in the study. This study demonstrated a
significant reduction in pain and analgesics requirement post-cryoablation, along with an
improvement in performance status. Additionally, mean and median survival was 15.9-
and 12.6-months post-treatment, with the 6-, 12-, and 24-month survival rates at 82.8%,
54.7%, and 27.3%, respectively. The absence of complications and reduction in cancer-
related pain in this study suggest that cryoablation is a palliative option for unresectable
LAPC. Limitations include the limited experience with the technology and the dearth of
high-quality data.
2.4.4. Photodynamic Therapy
In photodynamic therapy (PDT) visible or near-infrared light is used to activate a
light-sensitive drug or photosensitizer, (PS) which, in the presence of ground state oxygen,
creates reactive oxygen species and radicals that can induce tissue death [28,29]. Light is
delivered via small optic fibers placed percutaneously under image guidance. The first
phase I trial of PDT in locally advanced PDAC was conducted in 2002 by Bown et al. [30].
Tumor necrosis was achieved in all 16 patients included in the study. Median survival after
PDT was 9.5 mo (range 4–30 mo), and 44% (7/16) were alive one year after PDT. There was
tumor regrowth from the edges of treated areas. One of the drawbacks of the early PDT
treatments was that patients had to spend several days in subdued lighting following the
treatment to prevent complications from skin necrosis.
Verteporfin (Visudyne™, Valeant Pharmaceuticals, Bridgewater, NJ, USA) is a vascular-
targeted PS and can be administered just one hour before light treatment, and patients are
light-sensitive for only 24 h after treatment. Huggett et al. describe the results of a phase
I/II trial of verteporfin PDT on locally advanced pancreatic cancer [31]. Fifteen patients
with locally advanced cancers in the head of the pancreas and who could not undergo
surgical resection were given 0.4 mg/kg verteporfin. Necrotic volumes were determined
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for all patients, which increased with increasing light dose. The median survival after
I-PDT was 8.8 months and was comparable to patients undergoing conventional treatment.
The median survival from diagnosis was 15.5 months.
2.4.5. Irreversible Electroporation
Irreversible electroporation (IRE) uses a high-voltage, low-energy DC current as the
energy source, causing cellular injury by the creation of irreversible nanoscale defects
in the phospholipid bilayer of the cellular membrane (Figure 1), resulting in cellular
apoptosis [32,33]. IRE is primarily nonthermal and can achieve destruction of tumors
with sharp transition zones. Additionally, it spares vascular, ductal, and connective tissue
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Figure 1. (a) The anoKnife System. (b) NanoKnife IRE probe, 19-gauge needle with trocar tip with adjustable active probe
tip ranging from 0.5 to 4.0 cm.
IRE in the pancreas was initially studied in a swine model by Charpentier et al. and
was concluded to be a safe method for pancreatic tissue ablation [35]. The alterations to the
tumor microstructure in pancreatic cancer following irreversible electroporation ablation
were studied in a mouse model [36]. The purpose of this study was to elucidate morpho-
logical alterations following 30 min of IRE ablation in a mouse model of pancreatic cancer.
Early-passage PANC-1 cells were harvested and were implanted into both flanks of 14 mice.
A total of 3–4 weeks were allowed for tumor growth to a size of approximately 8 mm
(longest diameter for each tumor measured using calipers) prior to IRE procedures. These
mice were randomly divided into two groups: for the first group (n = 8), left-flank tumors
went untreated while right-flank tumors were treated with the IRE ablation protocol; for
the second group (n = 6), both left- and right-flank tumors were treated with IRE abla-
tion. Immunohistochemistry markers were compared with diffusion-weighted MRI (DWI)
apparent diffusion coefficient measurements before and after IRE ablation. Immunohisto-
chemistry apoptosis index measurements were significantly higher in IRE-treated tumors
than in controls. Rapid tissue alterations after 30 min of IRE ablation procedure, consisting
of structural and morphological alterations along with significantly elevated apoptosis
markers, were observed and correlated with apparent diffusion coefficient measurements.
This imaging assay demonstrated the potential to serve as an in vivo biomarker for the
noninvasive detection of tumor response in the pancreas following IRE ablation.
The initial human data on the use of IRE in pancreatic cancer were from the surgical
literature using an open approach [37]. This was followed by the percutaneous technique
using CT guidance. The first published percutaneous data in humans were from a retro-
spective cohort of 14 patients who had 15 ablations [38]. Three patients had metastatic
disease and eleven had LAPC. All patients had received chemotherapy previously, and
eleven had received radiation. The median tumor size was 3.3 cm (range, 2.5–7 cm). Two
patients were downstaged to surgery 4 and 5 months after IRE, respectively. Both had
margin-negative resections, and one had a complete pathologic response. This study es-
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tablished the feasibility of treating pancreatic cancer percutaneously and was followed by
another retrospective review of 50 patients with LAPC treated with percutaneous IRE [39].
The primary objective was safety, and the secondary objective was overall survival. Median
OS was 27 months (95% CI, 22.7–32.5 months) from the time of diagnosis and 14.2 months
(95% CI, 9.7–16.2 months) from the time of IRE. On multivariate analysis, tumors < 3 cm
had an OS significantly longer than those >3 cm, 33.8 vs. 22.7 months from the time of
diagnosis, and 16.2 vs. 9.9 months from IRE.
Edward Leen et al. published a retrospective review of seventy-five patients with
unresectable pancreatic carcinoma who underwent percutaneous IRE after chemotherapy
between 2011 and 2016 [40]. Median OS and PFS post-IRE for LAPC were 27 and 15 months,
respectively. Four patients with LAPC downstaged post-IRE ablation to surgery, with R0
resections in three cases.
The open and percutaneous approach of IRE in the pancreas were studied in a retro-
spective review of eight patients, where four were treated with an open approach and four
percutaneously with ultrasound guidance [41]. There were no patient deaths 90 days post-
IRE. There were five minor complications in three patients and four major complications
in three patients. The incidence of complications did not differ between approaches. The
median OS was 17.5 months from IRE and 24 months from diagnosis.
Figure 2 demonstrates a case example using IRE to treat unresectable LAPC. A 72-
year-old man, initially diagnosed with pancreatic adenocarcinoma in 2014, underwent
chemotherapy and IRE in 2014, and had external radiation to the neck of the pancreas.
Follow-up PET/CT 5 years later demonstrated FDG uptake within an ill-defined soft tissue
density inseparable from the pancreatic head at the level of the celiac trunk, concerning
for tumor recurrence. Patient also had elevated CA-19–9 levels. Repeat IRE treatment was











































Figure 2. (a) FDG-avid recurrent pancreatic mass (white thick arrow). (b,c) Two IRE probes in place
bracketing the mass (thin red arrows). (d) No residual FDG avidity post-treatment (red arrow).
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from diagnosis (95% CI: 15–19 months). In addition to the possible survival benefit of IRE,
the patients who received FOLFIRINOX before IRE did not demonstrate a survival benefit
compared with those who received gemcitabine or no chemotherapy before IRE (HR = 1.1;
p = 0.70). These results suggest that IRE was the key determinant for improved survival.
Additional work by He et al. compared the survival benefit in post-induction chemother-
apy patients treated with IRE vs. those treated with radiotherapy [44]. In this study,
thirty-six pairs of patients with LAPC were selected through propensity score matching
(PSM) analysis to compare the efficacy of the two treatments. After PSM analysis, a survival
benefit was identified in the IRE-treated group when compared to the radiotherapy-treated
group, with an improvement in both PFS and OS (2-year OS was 53.5% vs. 20.7%, p = 0.011;
2-year PFS rates were 28.4% vs. 5.6%, p = 0.004). Multivariate Cox regression analysis
indicated that IRE after induction chemotherapy was identified as a single favorable factor
for both OS and PFS in both the whole and matched cohort.
A more recent prospective study enrolled 54 patients (30 men; median age 61.0 years;
range 41–73 years) undergoing IRE with or without chemotherapy for pancreatic cancer
between July 2015 and August 2016 [45]. Thirty-one patients received IRE + chemotherapy
and 23 had IRE alone. Major IRE-related complications were observed in four patients
(7.4%). Among those with stage III disease, after a median follow-up of 18.8 months (range
9.6–28.7 months), the median OS from diagnosis was 16.2 and 20.3 months in the IRE and
IRE + Chemo groups, respectively. Among those with stage IV disease, after a median
follow-up of 13.3 months (range 3.7–23.1 months), the median OS from diagnosis was 11.6
and 13.56 months in the IRE and IRE + Chemo groups, respectively. The OS was significantly
poorer in the IRE group than in the IRE + Chemo group (log-rank test, p = 0.0398) [45].
CROSSFIRE (ClinicalTrial.gov, NCT02791503), a randomized, controlled, phase III
trial, is currently recruiting patients in Europe, comparing the outcome of FOLFIRINOX
plus IRE with FOLFIRINOX plus stereotactic ablative radiotherapy on OS for patients
with LAPC.
In the United States, the FDA provided the breakthrough designation status for IRE
in pancreatic cancer in 2018. This was followed by the investigational device exemption
approval, which paved the way for the first prospective multicenter trial from the US
to study IRE in a randomized, controlled fashion. This multicenter trial will involve
264 patients receiving IRE and 264 patients receiving standard of care treatment. The
primary endpoints will be OS and safety. Other endpoints will include PFS and pain scores.
Following induction chemotherapy with FOLFIRINOX, patients with inoperable biopsy
proven stage III pancreatic carcinoma will be randomized to IRE plus institutional standard
of care treatment and follow-up vs. institutional standard of care treatment and follow-up.
The IRE treatment can be offered by either a percutaneous or open surgical approach. The
study is currently enrolling (ClinicalTrial.gov, NCT03899636).
3. Post-Ablative Imaging in Pancreatic Cancer
With the advent and adoption of current locoregional treatments and future immune-
modulating agents, imaging response post-locoregional therapy in the pancreatic cancer
has not kept up with improvements in the treatment. The Response Evaluation Criteria
in Solid Tumors (RECIST) and RECIST 1.1 criteria have been used extensively since their
introduction, and concerns about using change in tumor size as the only criterion have not
been fully addressed, even in RECIST 1.1.
Pancreatic cancer is a desmoplastic neoplasm, hypo-vascularized and rich in fibrous
tissue, making it difficult to distinguish between residual/recurrent tumor and simple
fibrotic tissue. Katz et al. showed that the response of borderline resectable pancreatic
cancer to neoadjuvant therapy is not reflected by radiographic indicators and RECIST
response was not an effective treatment endpoint for patients with borderline resectable
pancreatic cancer [46].
Vroomen et al. studied the MR and CT imaging characteristics and ablation zone
volumetry of LAPC treated with IRE and concluded that the most remarkable signal
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alterations after pancreatic IRE were shown by DWI and contrast-enhanced MRI. Integrated
PET/MRI has been shown to provide an early response assessment in patients with
advanced pancreatic ductal adenocarcinoma (PDAC) [47]. A combination of MR and PET
scan along with markers will help to define the criteria to assess response to locoregional
treatment to the pancreas.
4. The Future of IRE
4.1. Immunomodulatory Effects of IRE
The stroma in pancreatic cancer prevents drug concentration and may be a reason for
the relatively poor response to chemotherapy in pancreatic cancer [48]. Immunotherapy
and immune checkpoint blockade have shown promise in different cancers but have
had limited efficacy against pancreatic cancer, and one of the proposed reasons is the
immunosuppressive stromal tissue. The stellate cells interact with cancer cells to modulate
cell proliferation and extracellular matrix production, evade immune surveillance, and
promote angiogenesis.
In a murine model study, IRE modulated the stroma, induced immunogenic cell death,
activated dendritic cells, and alleviated stroma-induced immunosuppression. IRE reversed
the resistance immune checkpoint blockade in pancreatic cancer and the study concluded
that IRE is a promising approach to potentiate the efficacy of immune checkpoint blockade
in pancreatic cancer [48].
Immune response following cryoablation and IRE was studied in a mouse model of
pancreatic cancer, and IRE was found to evoke a more robust infiltration of macrophages
and T cells than cryoablation within 24 h [49]. These recent results from animal studies
offer a glimpse into the future potential of IRE in mediating or enhancing the immune
response to pancreatic cancer. These preliminary animal studies provide a signal of the
future potential role of IRE and immunotherapies in pancreatic cancer.
4.2. High-Frequency IRE—An Emerging Technique
High-frequency irreversible electroporation (HFIRE) is an emerging technique that
uses bipolar square waves of 1–5 µs in rapid bursts, eliminating the need for intraoperative
paralytics and cardiac synchronization. This technique addresses the current limitations
associated with IRE by reducing the risks for cardiac asynchrony and muscle tetany. HFIRE
can also be performed with single-needle, dual-electrode devices, which eliminate the need
for a high level of technical skill typical of IRE to ensure accurate placement and alignment
of multiple electrodes for optimal treatment.
A preclinical feasibility study of a next-generation, single-needle, high-frequency
irreversible electroporation (SN-HFIRE) for pancreatic ablation has been performed using
an in vivo swine model. Six swine pancreases were treated with open SN-HFIRE without
intraprocedural paralytic medications or cardiac synchronization using varying voltage
waveform settings (on-off-on, 1-5-1, 2-5-2, or 5-5-5 µs, with a total energized time of
100 µs) [50]. This is a departure from the current IRE device, which requires paralytics
and cardiac synchronization. Key measured outcomes included intraprocedural muscle
twitch and cardiac activity, and ablation zone size and volume 6 h post-procedure. All
ablations were technically successful, with no change in muscle twitch or cardiac activity at
any pulse setting during the 5 min ablations and larger ablation areas (85 vs. 41/44 mm2)
and volumes (3344 vs. 1162 and 1339 mm3) using the 5-5-5 µs pulse setting. This feasibility
study supports the ability of SN-HFIRE to create rapid ablation zones in pancreatic tissue
without intraprocedural paralytic medications or cardiac synchronization.
Similarly, another recent preclinical study evaluated the safety and feasibility of
single-needle HFIRE for the treatment of hepatocellular carcinoma (HCC) in a canine
model [51]. Three canine patients with resectable HCC were treated with HFIRE (on-off-
on, 2-5-2 µS with a total energized time of 100 µS) without cardiac synchronization or
intraoperative paralytics. The authors evaluated the canine patients for adverse events
and measured the ablation volumes on post-treatment CT and the treatment-specific lethal
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thresholds for malignant and healthy liver tissue; they also assessed the HFIRE-induced
local immune response. Their results showed that HFIRE can be performed safely and
effectively and resulted in predictable ablation volume (average volume of 3.89 cm3 ± 0.74).
The lethal threshold was 710 V/cm ± 28.2. There were no adverse events reported and no
cardiac asynchrony or muscle tetany. Immunohistochemical analysis also demonstrated a
reactive proinflammatory margin surrounding the ablation zone, composed of collagen and
CD3+/CD4−/CD8− lymphocytes. This study further supported the safety and feasibility
of HFIRE and provided preliminary evidence that HFIRE is associated with a predictable
ablation volume and lymphocytic tumor infiltration.
Both studies provide promising results supporting the feasibility of this technique,
and they pave the way for broader applications of IRE, especially in patients who currently
cannot be treated with this technique due to cardiac contraindications. Nonetheless, larger
studies are still needed to validate these findings.
5. Conclusions
Pancreatic cancer is a complex disease and high-volume centers address this in a
multidisciplinary manner. The silent nature of pancreatic cancer and presentation leaves a
very small percentage of patients qualifying for surgery. Decades of conventional treatment
of pancreatic cancer, initially with chemotherapy and chemoradiotherapy, have not made a
significant impact on the overall survival of these patients. The synergistic capabilities of
local ablative therapies with imaging guidance are an attractive, minimally invasive option
which can be used in combination with traditional methods of treating pancreatic cancer.
One of the main limitations of all these innovative treatment options is the paucity of
level-one data. Among the several local ablative modalities reviewed, IRE has been shown
to be safe and effective, demonstrating a signal towards improved survival in several
studies. The prospective IRE trials that have been completed and are currently underway
overcome the limitation of the lack of randomized controlled trial data. The results of the
trials will help to answer some crucial questions regarding the role of this technology in
the treatment algorithm of pancreatic cancer.
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